We did not find a significant increase in the risk of neutropenia, diarrhea, and anemia (any grade or severe) in UGT1A1*28 heterozygous patients treated with SG as a single agent in comparison to UGT1A1 wild‐type patients (Online Supplementary Content, FigureS1). This evidence concerns the gene UGT1A1 and neutropenia.